Nike (NKE) is facing a tougher road back to growth which downgraded the stock to Underperform from Neutral and cut its price target sharply to $30 from $47
BIOX posted sizable FY26 losses and sharply lower equity but gained extra time on Nasdaq’s bid-price deficiency as cost cuts lift quarterly Adjusted EBITDA into positive territory.
